Modern view on treatment of membranous nephropathy

Cover Page


Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults. Since the moment of animal model creation and the recognition of podocytes damage as a key mechanism of MN development, the identification of antigens, first of all the phospholipase A2 receptor (PLA2R), and the development of methods of PLA2R autoantibodies detection and its monitoring opened a new era in the idiopathic MN (iMN) diagnosis, treatment and prognosis evaluation. MN continues to be actively studied in the new millennium, since a number of aspects of its pathogenesis still need to be clarified, and there is still no clear opinion on the iMN treatment optimal approach.

Comprehensive clinical and serological assessment of patients with iMN can be the key to individual choice of treatment protocols. In patients with aPLA2R-positive iMN, the predictor of disease remission is the aPLA2R titer decrease or aPLA2R disappearance in the blood serum, and disease relapse is associated with the aPLA2R appearance ore increase of aPLA2R titer in the circulation. Studies which were conducted by today (GEMRITUX, MENTOR, STARMEN, NICE, etc.) confirmed the acceptable safety profile and effectiveness of iMN therapy by anti-CD20 monoclonal antibodies (rituximab): more than half of of iMN patients had remission of nephrotic syndrome or proteinuria decrease, remissions in anti-CD20 monoclonal antibodies treated patients were longer compared to traditional therapy. The obtained data allows us to consider rituximab and anti-CD20 antibody therapy of a new generation not only as an alternative to the more toxic treatment with cyclophosphane and calcineurin inhibitors, but as an independent promising direction of therapy for patients with IMN, which completely changes the paradigm of treatment of this glomerulopathy.

Full Text

Restricted Access

About the authors

Irina N. Bobkova

Sechenov First Moscow State Medical University (Sechenov University)

ORCID iD: 0000-0002-8007-5680

Russian Federation, Moscow

д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии

Elena S. Kamyshova

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
ORCID iD: 0000-0002-1823-0125

Russian Federation, Moscow

к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии


  1. Бобкова И.Н., Кахсуруева П.А., Ставровская Е.В., Филатова Е.Е. Эволюция в понимании патогенеза идиопатической МН – от экспериментальных моделей к клинике. Альманах клинической медицины. 2017;45(7):553-64 [Bobkova IN, Kahsurueva PA, Stavrovskaja EV, Filato- va EE. Jevoljucija v ponimanii patogeneza idiopaticheskoj MN – ot jeksperimental’nyh modelej k klinike. Al’manah klinicheskoj mediciny. 2017;45(7):553-64 (In Russ.)]. doi: 10.18786/2072-0505-2017-45-7-553-564
  2. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. doi: 10.1056/NEJMoa0810457
  3. Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364(7):689-90. doi: 10.1056/NEJMc1011678
  4. Hu SL, Wang D, Gou WJ, et al. Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis. J Nephrol. 2014;27:111-6. doi: 10.1007/s40620-014-0042-7
  5. Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26:2545-58. doi: 10.1681/ASN.2014070640
  6. Jullien P, Seitz Polski B, Maillard N, et al. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy. Clin Kidney J. 2017;10:209-14. doi: 10.1093/ckj/sfw121
  7. Polanco N, Gutiérrez E, Covarsí A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697-704. doi: 10.1681/ASN.2009080861
  8. Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993;329(2):85-9. doi: 10.1056/NEJM199307083290203
  9. Troyanov S, Wall CA, Miller JA, et al.; Toronto Glomerulonephritis Registry Group. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2004;66(3):1199-205. doi: 10.1111/j.1523-1755.2004.00873.x
  10. Glassock RJ. The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am J Kidney Dis. 2004;44(3):562-6.
  11. Ruggenenti P, Cravedi P, Remuzzi G. Latest treatment strategies for membranous nephropathy. Expert Opin Pharmacother. 2007;8(18):3159-71. doi: 10.1517/14656566.8.18.3159
  12. Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 2013;9(8):443-58. doi: 10.1038/nrneph.2013.125
  13. Perna A, Schieppati A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004;44(3):385-401. PMID: 15332211
  14. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int (Suppl.). 2012; 2:139-274.
  15. Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis [published correction appears in Am J Kidney Dis. 2017 Mar;69(3):485]. Am J Kidney Dis. 2013;62(3):403-41. doi: 10.1053/j.ajkd.2013.06.002
  16. Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet. 2013;381(9868):744-51. doi: 10.1016/S0140-6736(12)61566-9
  17. Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1984;310(15):946-50. doi: 10.1056/NEJM198404123101503
  18. Ponticelli C, Zucchelli P, Passerini P, Cesana B. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med. 1992;327(9):599-603. doi: 10.1056/NEJM199208273270904
  19. Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18(6):1899-904. doi: 10.1681/ASN.2007020166
  20. Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001;59(4):1484-90. doi: 10.1046/j.1523-1755.2001.0590041484.x
  21. Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924-30. doi: 10.1038/
  22. McQuarrie EP, Stirling CM, Geddes CC. Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy. Nephrol Dial Transplant. 2012;27(1):235-42. doi: 10.1093/ndt/gfr220
  23. Van den Brand JAJG, Ruggenenti P, Chianca A, et al. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. J Am Soc Nephrol. 2017;28(9):2729-37. doi: 10.1681/ASN.2016091022
  24. Fitzpatrick L, Kaiser M, Stewart BH, Hoskin DW. Effect of interferon-gamma, interleukin-2 and interleukin-4 on cyclosporin-A-mediated inhibition of anti-CD3-induced T-lymphocyte proliferation. Int J Immunopharmacol. 1994;16(4):289-93. doi: 10.1016/0192-0561(94)90003-5
  25. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931-8. doi: 10.1038/nm.1857
  26. Mathieson PW. Proteinuria and immunity – an overstated relationship? N Engl J Med. 2008;359(23):2492-4. doi: 10.1056/NEJMcibr0806881
  27. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7(8):455-65. doi: 10.1038/nrclinonc.2010.82
  28. Seitz-Polski B, Dahan K, Debiec H, et al. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. Clin J Am Soc Nephrol. 2019;14(8):1173-82. doi: 10.2215/CJN.11791018
  29. Alfaadhel T, Cattran D. Management of Membranous Nephropathy in Western Countries. Kidney Dis (Basel). 2015;1(2):126-37. doi: 10.1159/000437287
  30. Biancone L, Andres G, Ahn H, et al. Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis. Kidney Int. 1995;48(2):458-68. doi: 10.1038/ki.1995.314
  31. Kerjaschki D, Neale TJ. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol. 1996;7(12):2518-26.
  32. Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol. 1982;128(6):2453-7.
  33. Zhu LP, Cupps TR, Whalen G, Fauci AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest. 1987;79(4):1082-90. doi: 10.1172/JCI112922
  34. Remuzzi G, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy [published correction appears in Lancet 2002 Dec 21-28;360(9350):2090]. Lancet. 2002;360(9337):923-4. doi: 10.1016/S0140-6736(02)11042-7
  35. Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017;13(9):563-79. doi: 10.1038/nrneph.2017.92
  36. Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol. 2003;14(7):1851-7. doi: 10.1097/01.asn.0000071511.35221.b3
  37. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008;73(1):117-25. doi: 10.1038/
  38. Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. 2010;5(12):2188-98. doi: 10.2215/CJN.05080610
  39. Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(8):1416-25. doi: 10.1681/ASN.2012020181
  40. Dahan K, Debiec H, Plaisier E, et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol. 2017;28(1):348-58. doi: 10.1681/ASN.2016040449
  41. Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46. doi: 10.1056/NEJMoa1814427
  42. Scolari F, Dallera N, Gesualdo L, et al. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. BMJ Open. 2019;9(12):e029232. Published 2019 Dec 4. doi: 10.1136/bmjopen-2019-029232
  43. Waldman M, Beck LH Jr, Braun M, et al. Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab. Kidney Int Rep. 2016;1(2):73-84. doi: 10.1016/j.ekir.2016.05.002
  44. Waldman M, Austin HA, Balow JE. Rituximab or Cyclosporine for Membranous Nephropathy. N Engl J Med. 2019;381(17):1688. doi: 10.1056/NEJMc1910393
  45. Rojas-Rivera J, Fernández-Juárez G, Ortiz A, et al. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study. Clin Kidney J. 2015;8(5):503-10. doi: 10.1093/ckj/sfv075
  46. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960-8. doi: 10.1002/art.27314
  47. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-33. doi: 10.1002/art.27233
  48. Tang R, Yu J, Shi Y, et al. Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis. Int Immunopharmacol. 2020;83:106389. doi: 10.1016/j.intimp.2020.106389
  49. Wang Z, Bao HW, Ji Y. A systematic review and meta-analysis of rituximab combined with methotrexate versus methotrexate alone in the treatment of rheumatoid arthritis. Medicine (Baltimore). 2020;99(8):e19193. doi: 10.1097/MD.0000000000019193
  50. Ruggenenti P, Cravedi P, Remuzzi G. Rituximab for membranous nephropathy and immune disease: less might be enough. Nat Clin Pract Nephrol. 2009;5(2):76-7. doi: 10.1038/ncpneph1007
  51. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2007;2(5):932-7. doi: 10.2215/CJN.01180307
  52. Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543-50. doi: 10.1681/ASN.2010111125
  53. Frerichs KA, Nagy NA, Lindenbergh PL, et al. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. Expert Rev Clin Immunol. 2018;14(3):197-206. doi: 10.1080/1744666X.2018.1443809
  54. Schriewer L, Schütze K, Petry K, et al. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics. 2020;10(6):2645-58. doi: 10.7150/thno.38533
  55. Barrett C, Willcocks LC, Jones RB, et al. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol Dial Transplant. 2019;gfz086. doi: 10.1093/ndt/gfz086
  56. Ruggenenti P, Remuzzi G. A First Step toward a New Approach to Treating Membranous Nephropathy. N Engl J Med. 2019;381(1):86-8. doi: 10.1056/NEJMe1906666



Abstract - 46

PDF (Russian) - 8





  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies